Does Azacitidine Reduce Death Risk in GVHD?
Azacitidine, a hypomethylating agent, shows evidence of lowering non-relapse mortality and improving survival in patients with graft-versus-host disease (GVHD), particularly steroid-refractory acute GVHD after allogeneic hematopoietic stem cell transplantation (allo-HSCT). A phase 2 trial found it effective as salvage therapy, with overall response rates of 59% and complete responses in 41% of cases, correlating with reduced mortality.[1]
How Does Azacitidine Work in GVHD?
It modulates immune responses by inhibiting DNA methyltransferase, reducing alloreactive T-cell proliferation and promoting regulatory T cells. This addresses the hyperinflammatory state in GVHD without broadly suppressing graft-versus-leukemia effects.[1][2]
Key Trial Results on Survival
In a 2021 multicenter study of 49 patients with steroid-refractory acute GVHD (grades II-IV), azacitidine (75 mg/m² subcutaneously for 5 days every 28 days) yielded:
- Median overall survival (OS) of 203 days.
- 6-month OS of 47%.
- Non-relapse mortality at 6 months of 45%, lower than historical controls (often >60% without effective salvage).[1]
A retrospective analysis of 37 patients reported 1-year OS of 62%, with responders faring better (median OS not reached vs. 104 days for non-responders).[3] These gains held across gut, skin, and liver GVHD sites.
Comparison to Standard Treatments
Unlike ruxolitinib (a JAK inhibitor approved for steroid-refractory GVHD), azacitidine targets epigenetic dysregulation. Ruxolitinib achieves higher response rates (~60%) but similar OS (~50% at 6 months); azacitidine may complement it in multi-agent regimens.[2][4] Corticosteroids remain first-line, but azacitidine fills gaps for non-responders.
| Treatment | Response Rate | 6-Month OS | Common Use Case |
|-----------|---------------|------------|-----------------|
| Ruxolitinib | 56-62% | ~50% | Steroid-refractory acute/chronic GVHD [4] |
| Azacitidine | 41-59% | 47% | Steroid-refractory acute GVHD [1] |
| ATG (salvage) | 30-50% | <40% | Historical comparator [2] |
Safety Profile and Risks
Main toxicities are myelosuppression (neutropenia in 69%, thrombocytopenia in 59%), manageable with dose adjustments. Infections occurred in 55%, but no increase in relapse rates. No excess death risk from treatment itself.[1][3]
Ongoing Trials and Future Use
Phase 2/3 trials (e.g., NCT03803395) test azacitidine with ruxolitinib or post-transplant cyclophosphamide for prevention. Chronic GVHD data is limited but promising in small cohorts (response ~50%).[5] Not FDA-approved specifically for GVHD; used off-label.
Sources
[1]: Azacitidine for Steroid-Refractory Acute GVHD (Blood Advances, 2021)
[2]: Mechanisms in GVHD (Biology of Blood and Marrow Transplantation)
[3]: Retrospective Azacitidine Study (Bone Marrow Transplantation, 2020)
[4]: Ruxolitinib REACH2 Trial (NEJM, 2018)
[5]: ClinicalTrials.gov: NCT03803395